Despite a high prevalence of chronic kidney disease (CKD) among women, diagnosis is often delayed and women are less likely to receive critical treatments like dialysis or a kidney transplant compared to men, according to a new American Heart Association (AHA) scientific statement published in the association’s flagship journal Circulation.
The statement suggests improving women’s kidney care by recognising how women’s unique biology and social factors affect kidney health and designing research that includes sex-specific analyses of kidney function and CKD medications.
“Many cases go undiagnosed in women because common tests and research do not always reflect women’s biology and life stages,” said Eman Y Gohar (Vanderbilt University Medical Center, Nashville, USA), the volunteer chair of the scientific statement writing group.
“Biological differences include genetics, sex chromosomes, hormones, immune-system responses and differences in how the body processes and responds to medication,” Gohar said. “We also need to acknowledge female-specific factors that do not apply in the same way to male patients. These include menstrual health, pregnancy, postpartum changes and menopause as well as socioeconomic factors like financial barriers or cultural expectations. Each of these creates considerations that are unique to women and may require tailored care.”
The scientific statement, lists seven challenges women face in kidney care, including: underrepresentation in clinical trials, less treatment access, delayed referrals, adverse pregnancy outcomes, menopause, more adverse effects of kidney treatment medication, lower rates of kidney transplant and medication effects and underrepresentation in clinical trials.
According to the statement, women may have different responses to kidney treatment medication compared to men but continue to remain underrepresented in clinical trials.
“Women are not simply smaller versions of men,” said Gohar. “Their biology, reproductive life stages and responses to medication may differ, and those differences need to be reflected in clinical care and research.”
Women and men may respond differently to medications because of differences in how they are absorbed, distributed, broken down and removed from the body. In fact, laboratory research points to oestrogen receptors as having a potential role in women’s kidney function.
Kidney function is commonly estimated using creatinine, a waste product generated by muscle. Because women typically have less muscle mass and may produce less creatinine, these estimates may not always accurately reflect kidney function, thus causing kidney disease in some women to be misclassified or recognised later.
Understanding aspects of kidney health that are unique to women’s life stages is critical for advancing precision medicine.
“Kidney health and reproductive health are intertwined,” Gohar said. “Pregnancy, menstrual health and menopause may provide important information about a woman’s current and future kidney health.”
Pregnancy in women with CKD may increase the risk of kidney disease progression and pregnancy complications. Taking steps to manage blood pressure, blood sugar and body weight is suggested for women with CKD who plan to become pregnant.
In women without CKD, pregnancy complications such as preeclampsia may signal an increased risk of future kidney disease, heart disease and stroke.
Natural menopause before age 45 and surgical removal of the ovaries before age 50 are each linked with a higher risk of CKD. Other factors contributing to CKD after menopause include increases in obesity, type 2 diabetes and high cholesterol.
The statement suggests that embedding reproductive health assessment in CKD care is one step towards advancing precision kidney medicine.
In addition to pregnancy and menopause, other women-specific conditions affect CKD risk. Polycystic ovary syndrome, a common hormone disorder among women, and the autoimmune disease lupus, which is more common in women than men, are linked with a higher risk of CKD.
The scientific statement was prepared by the volunteer writing group on behalf of the American Heart Association’s Kidney in Cardiovascular Disease Committee of the Council on the Kidney in Cardiovascular Disease; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health.
